Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) traded up 7.8% during trading on Monday after an insider bought additional shares in the company. The stock traded as high as $10.50 and last traded at $10.35, with a volume of 2,722,149 shares changing hands. The stock had previously closed at $9.60.

Specifically, insider Barbara White purchased 4,233 shares of the company’s stock in a transaction that occurred on Friday, March 17th. The shares were bought at an average cost of $9.49 per share, for a total transaction of $40,171.17. Following the purchase, the insider now owns 166,300 shares of the company’s stock, valued at approximately $1,578,187. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 11.60% of the company’s stock.

CRBP has been the topic of several recent analyst reports. Noble Financial reiterated a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Sunday, March 12th. Cantor Fitzgerald reiterated a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Thursday, February 16th. Finally, Aegis reiterated a “buy” rating and issued a $12.00 target price on shares of Corbus Pharmaceuticals Holdings in a research note on Wednesday, November 30th.

The stock has a 50 day moving average of $8.19 and a 200-day moving average of $7.50. The stock’s market cap is $504.06 million.

Several hedge funds have recently made changes to their positions in CRBP. Milestone Group Inc. bought a new stake in shares of Corbus Pharmaceuticals Holdings during the third quarter worth approximately $102,000. Bainco International Investors bought a new stake in shares of Corbus Pharmaceuticals Holdings during the third quarter worth approximately $136,000. Private Advisor Group LLC bought a new stake in shares of Corbus Pharmaceuticals Holdings during the fourth quarter worth approximately $201,000. Gilder Gagnon Howe & Co. LLC bought a new stake in shares of Corbus Pharmaceuticals Holdings during the third quarter worth approximately $508,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of Corbus Pharmaceuticals Holdings during the fourth quarter worth approximately $854,000. Hedge funds and other institutional investors own 25.91% of the company’s stock.

Your IP Address:

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.

5 Day Chart for NASDAQ:CRBP

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.